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macular degeneration (AMD). METHODS: A systematic review of literature was
conducted. The bibliographic search covered the period between January 1996 and
January 2011. The search was run on MEDLINE, EMBASE, Cochrane library, INAHTA
and ECRI. The criteria employed to select the papers were: population (AMD pa-
tients), treatment (Ranibizumab or Bevacizumab), comparison (placebo or other
active treatments). To assess the efficacy, it was decided to include systematic
reviews and randomised clinical trials (RCT). For the safety, it was considered any
type of study. RESULTS: The bibliographical search retrieved 731 references of
articles and 51 papers were finally included: 4 were controlled clinical trials: two on
Ranibizumab and two on Bevacizumab. Efficacy: Ranibizumab and Bevacizumab,
as compared to placebo as to Verteporfin, gets results in terms of AMD stabilization
(between 0 and 1.2% of severe visual losses as opposed to 13-16% in the control
groups), in terms of reduction in the lesion size and it even achieves improvement
in visual acuity in some cases. Safety: The adverse effects (of any magnitude) were
more frequent in the groups treated with Ranibizumab and Bevacizumab than in
the control groups (placebo and Verteporfin). The data’s synthesis showed adverse
effects similar in both drugs. Economic Evaluation: Drug costs for 1 year of treat-
ment were estimated as 2.330€ for Ranibizumab and 53€ for Bevacizumab.
CONCLUSIONS: : Both drugs provide startling benefits in the treatment of age-
related macular degeneration (AMD). Cost effectiveness analysis of bevacizumab
makes this intervention highly cost effective versus ranibizumab. The price of
ranibizumab would have to be drastically reduced for it to be cost effective. Public
pressure may be the most potent weapon in persuading Genentech to license
bevacizumab for AMD.
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OBJECTIVES:To characterize the economic and societal burden of Diabetic Macular
Edema (DME) in Canada. METHODS: Patients with clinically significant macular
edema (CSME) were enrolled by ophthalmologists or retinal specialists across Can-
ada. Patients are followed over a 6-month period to combine prospective data
collected during monthly telephone interviews and at sites at months 0, 3 and 6.
Visual acuity (VA) is measured and DME-related health care resource information
is collected. Patient health-related quality of life is measured using the National
Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), and the EuroQol Five
Dimensions (EQ-5D). The 3-month results are available and presented here.
RESULTS: A total of 145 patients [mean age 63.8 years (range: 30-86 yrs); 52% male;
81% Type 2 diabetes; mean duration of diabetes 18 years (range: 1-62 yrs); 72%
bilateral CSME] were enrolled from 17 sites across 6 provinces in Canada. At base-
line, the mean VA was 20/60 (range: 20/20-20/800) across all eyes diagnosed with
CSME (249 eyes). Sixty-eight percent of patients had VA severity in the worse seeing
eye of normal/mild vision loss (VA 20/10 to  20/80), 19% moderate vision loss (VA
 20/80 to  20/200), and 13% severe vision loss/nearly blind (VA  20/200). At
month 3, the mean NEI VFQ-25 composite score was 79.9, the mean EQ-5D utility
score was 0.79, and the EQ visual analogue scale score was 70.6. The average
3-month DME-related cost per patient was $1,487 across all patients (95% confi-
dence interval: $1,164 to $1,810). The cost was $1,390 for patients with normal/mild
vision loss, $1,831 for patients with moderate vision loss, and $1,467 for patients
with severe vision loss/nearly blind. CONCLUSIONS: DME is associated with limi-
tations in functional ability and quality of life. In addition, the DME-related cost is
substantial to the Canadian health care system.
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ECONOMIC BURDEN OF PSORIASIS AND DIABETES IN PATIENTS WITH
PSORIASIS IN THE UNITED STATES
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OBJECTIVES: Psoriasis, an immune mediated disorder with skin manifestations
and comorbidities, has high resource requirement. Specifically, diabetes is highly
prevalent in psoriasis patients and may represent a substantial incremental eco-
nomic burden. This retrospective study aimed to estimate the incremental costs of
psoriasis and diabetes in psoriasis patients. METHODS: Adult patients with psori-
asis (i.e., 2 psoriasis diagnoses ICD-9 codes:696.1x) were selected from a large US
administrative claims database. Psoriasis-free controls were matched with the
psoriasis sample by age and gender in a 1:1 ratio. All patients were followed for one
year to assess their healthcare costs. Incremental total healthcare costs (USD 2010)
associated with psoriasis and diabetes in a psoriasis population, measured from a
third-party payer perspective, were estimated using regression models controlling
for age and gender. RESULTS: A total of 106,128 matched pairs were studied.
Among psoriasis patients, 16% had diabetes compared to 13% of the psoriasis-free
controls (p.001). Psoriasis was associated with a $4,523 adjusted increment total
health care costs among patients without diabetes ($10,017 vs. $5,539; p.001),
compared to $5,984 among patients with diabetes ($19,536 vs. $13,589; p.001). In
the psoriasis population, diabetes presented a $8,337 adjusted incremental cost
compared to the psoriasis patients without diabetes ($19,536 vs. $10,017; p.001).
This was $1,460 more than the adjusted incremental costs from diabetes among
controls without psoriasis (p.001), representing an interaction of psoriasis and
diabetes conditions, which significantly increases the health care costs.
CONCLUSIONS: Both psoriasis and diabetes are expensive conditions to treat. The
incremental economic burden of patients having both diseases is significantly
higher than each condition individually, potentially due to the complexity of man-
aging both conditions at the same time.
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OBJECTIVES: Analyse the burden of chronic hand eczema (CHE) patients with ep-
isodes of severe disease preceding the availability of the first approved systemic
treatment in 2008. METHODS: In this cost-of-illness study, 310 patients with CHE
refractory to topical steroids in Germany were analyzed (patients with coverage by
statutory (GKV) or occupational health insurances (BG)). The cross-sectional survey
instrument collected data on patient characteristics, clinical status (i.e. max. se-
verity in past year and at inclusion) and resource use. Only patients with severe
disease (photographic guide) in the year preceding this study were selected for this
analysis. The following aspects were investigated: resource use, costs, clinical sta-
tus (at inclusion) and quality of life (DLQI). RESULTS:A total of 161 (52 %) of the CHE
patients had severe CHE during the last 12 months (similar fractions in both insur-
ances categories) and 74 % of these patients reported a moderate/severe disease
status (Physician global assessment (PGA)) at inclusion. The average DLQI score at
inclusion was 8.1 (moderate effect on patient’s life). Approximately half of the
patients received only topical treatments, while the remaining patients received a
combination of topical therapies with UV-therapy (68 %) and/or systemic therapies
(36%). The yearly health care costs of these patients were €2221 (GKV patients) and
€3961 (BG). CONCLUSIONS: Among these CHE patients refractory to topical corti-
costeroids, half of the patients had severe disease during the year prior to the
survey. Despite the extensive usage of health care resources (incl. UV-therapy,
off-label systemic therapies and hospitalization), the CHE disease severity state did
not change considerably for most patients. It remains to be seen whether the
availability of the first approved systemic treatment (alitretinoin) for severe CHE
will change the dynamics seen in this disease and therefore, further prospective
studies are warranted to clarify this aspect.
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OBJECTIVES: Tinnitus has a major effect on quality of life when it occurs for a
longer period of time. It is a conservative estimate that 10% of the general popula-
tion experiences spontaneous prolonged tinnitus. The aim of this study is to esti-
mate the burden and cost of tinnitus in Hungary from three different perspectives,
as no publicly available cost or burden of illness study has been found in this field.
The objective is to fill this gap in the Hungarian setting. METHODS: The present
study identified both the costs that are made and the resources that are lost in the
form of direct medical and nonmedical costs and indirect costs associated with
tinnitus. An expert panel based estimate was used to identify probabilities for the
different paths and resource use, due to lack of information in the literature. Direct
medical costs were observed from the National Health Insurer’s (NHI) database,
while the indirect costs were estimated according to the human capital approach.
The cost estimates were based on a model structured by a decision tree. RESULTS:
An annual cost of 91,891Ft (€ 328) has been estimated for a newly diagnosed tinni-
tus patient. The average treatment cost borne by the NHI is 6,363Ft (€ 23), while a
37,534Ft (€ 134) cost was assigned to the diagnosis of a typical patient attending an
ENT specialist. Indirect cost consist of sick leave cost which is 861Ft (€3.1), 3,118Ft
(€11) and 8,743Ft (€31) in the different cost categories of NHI costs, out of pocket
costs and societal costs, respectively. CONCLUSIONS: From the societal perspec-
tive, the annual cost of tinnitus amounted for 0.01% of the Hungarian GDP in 2009
which is almost evenly borne by the NHI and the population with tinnitus. There is
little information in either the Hungarian or the international literature to validate
the model against.
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OBJECTIVES: Literature concerning epidemiology of blindness and with these dis-
ease patterns associated economic consequences is very rare. The aim of this
analysis was to close this research deficit for Austria by evaluating the whole
economic impact of blindness for the Austrian society using the incidence
approach. METHODS: A model that captures all causes of blindness (AMD, glau-
coma, diabetic retinopathy, cataract, and other causes) was developed. We differ-
entiated between age groups as well. Cost of illness comprises direct medical cost
(treatment, consultations, devices, cost of depression, hip fractures etc.) and direct
non-medical cost (adaption of housing facilities). Indirect cost are allowance for
nursing care, cost for assisted living and productivity loss. The analysis was per-
formed from a society’s perspective. Cost are calculated from onset of blindness
until death (reduced life expectancy due to blindness) (dicount rate 5%). The anal-
ysis was performed according to the Austrian Guidelines for Healtheconomic
evaluations. RESULTS: In Austria every year 1160 (Incidence) people go blind. Total
cost (direct and indirect) of blindness over all age groups value €105.71 Mio. (incl.
allowance for nursing care) over lifetime. Direct cost account for 3% of total cost
(€3.61 Mio.) and indirect cost for 97% (€102.09 Mio.). Highest cost of blindness over
lifetime can be found within the groups ,opticusatrophy‘ (18-39-year-old-patients)
with 11.77 Mio., diabetic retinopathy‘ (60-79-year-old-patients) with cost of €7.02
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Mio, and, other causes‘ (18-39 year old patients) with €33.80 Mio. CONCLUSIONS: A
multitude of causes for blindness affects primarily older people. Demographic de-
velopment will lead to an increase in blind people and therefore to a costly public
health problem. Loosing eyesight is connected to high cost on the one hand and to
a lower QOL for patients on the other hand. The analysis shows the high cost of
blindness for the whole society in Austria.
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OBJECTIVES: Blindness represents significant burden of disease worldwide. The
aim of this research is to estimate medical and non medical expenses related to
blindness of elderly patients (60 years) in Hungary so that results can be used for
further policy analyses. METHODS: Inputs for burden of disesase model were de-
rived from the published literature, statistical databases and structured interviews
with relevant experts. We divided the burden of elderly blindness into public and
private medical and non medical costs. In addition to direct costs (social care and
subvention, conduct recourse, medical costs) indirect costs and lost revenues (un-
employment, support to activities of daily living) were also calculated. RESULTS:
The social burden of 6051 elderly blind patients was estimated 53.35 million USD in
2009, 0.03% of the Hungarian GDP (1 USD 128.19 HUF in purchasing power parity
exchange rate). Social care and subventions (20.04 million USD), support to daily
living activities (15.91 million USD) and healthcare costs (6.68 million USD) repre-
sented the largest proportion of expenses. 55% of total burden were derived from
public sector and within public burden social care and subventions represented
two-third of expenses. CONCLUSIONS: The societal burden of elderly blindness is
significant even without measuring its impact on mortality and quality of life. It is
important to redefine the necessary health and social policy objectives of preven-
tion, health care and social integration of elderly blindness. Further research is
needed to measure the impact of medical and non-medical interventions to reduce
the societal burden of elderly blindness
PSS18
DIRECT ECONOMIC BURDEN OF REGULAR INTRAVITREAL INJECTIONS FOR THE
TREATMENT OF RETINA DISEASES IN THREE EUROPEAN COUNTRIES
Johnson MK1, Lara N2
1Allergan EAME, Parkway, Marlow, Bucks SL7 1YL, UK, 2IMS Health, Barcelona, Barcelona,
Spain
OBJECTIVES: Retina disease (RD) is a leading cause of blindness in Europe with
significant clinical and economic consequences. The research objective was to
assess the direct health care resource use of patients receiving regular intravitreal
injections (rIVI) to treat RD in France, Spain and the UK (UK). METHODS: Three
focus group sessions were performed with at least 6 retina specialists who treated
RD patients with rIVIs (defined as IVIs every 4 to 6 weeks). A specific questionnaire
assessed resource use including medical visits, diagnostic/monitoring tests and
procedures, drugs administered, IVI adverse event treatment, surgery and trans-
port. Costs were quantified using official and bibliographical sources from each
national health care system perspective over a one-year time horizon. All costs are
expressed in 2010 euros and pound sterling. RESULTS: The annual total direct
health care cost per patient treated with rIVI was €14,725 in France, €10,027 in Spain
and £9,647 to £13,759 in the UK (depending on the setting of care: outpatient or day
case). In all countries, pharmacological costs accounted for the largest proportion
of overall costs (50-80%). Ranibizumab was the most used drug except some coun-
tries that reported off-label use of bevacizumab. Non-pharmacological costs, in-
cluding follow-up visits, tests and administration costs, were €2353, €2918 and
£3000-£9096 in France, Spain and the UK, respectively. CONCLUSIONS: Treatment
with rIVIs is costly to health care systems. While drug costs account for a large
portion of costs, required monitoring is a key cost driver and affects health care
systems’ capacity to treat RD patients. Any strategy to reduce the number of rIVIs
per year would assist in reducing the burden on health care systems. Furthermore,
to assess the full cost of treatment, a study assessing direct cost to patients and
caregivers and indirect cost is also needed.
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OBJECTIVES:Ocular hypertension (OHT) and primary open-angle glaucoma (POAG)
are chronic eye conditions that progress over time, potentially leading to blindness.
Glaucoma management costs increase with disease severity and treatment
switches, drugs and surgical treatments being cost drivers. Our study aimed to
estimate this glaucoma management costs as a function of the disease stage and
the number of treatment changes in Germany. METHODS: We analyzed patient-
level data from an observational study with retrospective collection of medical
resources used by German glaucoma patients over a 5-year period. Associated
costs were derived for drug treatment, medical/surgical procedures, exams/tests
and hospitalizations (Statutory Health Insurance, 2009 costs). A linear regression
was performed on the total management costs and drug costs, with two indepen-
dent variables: the current disease stage (OHT [reference], early, moderate, ad-
vanced POAG), and the number of treatment changes (0 [reference], 1, 2, 3
changes). Costs were estimated against the reference category (OHT-No change).
RESULTS: Data from 154 OHT/POAG patients (57% female, mean age 67 /11
years) was analyzed. OHT patients without treatment change had a mean (SD) total
management cost of €123 (121) per year, which increased by €71 (p0.05), €153
(p0.05) and €398 (p0.004) in disease stages early, moderate and advanced POAG
respectively. Each treatment line change (1, 2, 3) also resulted in increase in cost
of €45 (p0.05), €177 (p0.05) and €451 (p0.0001) compared to the reference cost,
respectively. The drug cost followed the same pattern, with a mean (SD) reference
cost of €83 (33) per year and increases by €70 (p0.05), €88 (p0.022) and €160
(p0.0001) with the disease stage, and €22 (p0.05), €76 (p0.044) and €146
(p0.0001) with each treatment change. CONCLUSIONS: The analysis of observa-
tional data showed a significant increase of the glaucoma management costs with
both the disease severity and the number of treatment changes.
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OBJECTIVES: To estimate the mean annual cost of the different biological agents
licensed for the treatment of patients with moderate to severe plaque psoriasis
during the first year of treatment and maintenance, according to the daily clinical
practice in Spain. METHODS: Data were obtained from case notes of a sequential
patient cohort with psoriasis attending a tertiary referral severe psoriasis service
and initiated on biologics for treatment of their psoriasis at least 12 months before
to the cut-off date (November 2010). Data on drug usage (dose and dosage, starting
and changing dates), that patients have experienced throughout the treatment,
were collected To estimate the annual drug cost for each patient, two periods of
time were considered in the analysis: first year after initiation of biologic therapy
and the year before the cut-off as maintenance period. Specific assumptions re-
garding the dosage, interruption, or switching to other biological after initiation of
treatment were set out. Only the cost of biological agents was considered, regard-
less of any other associated expenses, dismissing those subjects who have been on
therapy less than 3 months before switching to other biological drug.RESULTS:The
primary analysis population comprised a total of 760 patients: adalimumab
(n212), etanercept (n214), infliximab (n145), and ustekinumab (n189). These
subgroups were comparable in age, gender, weight, type of psoriasis, severity, joint
affectation and concomitant diseases prevalence. The mean annual costs were: for
adalimumab 13,346.48 € and 12,120.09 €, etanercept 15,268.28 € and 14,420.46 €,
infliximab 16,589.67€ and 13,889.49 €, and ustekinumab 18.370,50 € and 15.500,44 €.
CONCLUSIONS: The current cost analysis clearly shows that the expenditure as-
sociated with the use of adalimumab both, at the initiation of therapy and main-
tenance, reflects the lowest price charged for a biological drug in patients with
moderate to severe plaque psoriasis, in daily clinical practice in Spain.
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OBJECTIVES: The aim of the study was to analyse and estimate health-related
quality of life (HRQoL), costs of psoriasis during 12 months and disease severity
among patients with psoriasis in Denmark who had received different types of
treatment. METHODS: The study is based on 131 patients included from three
dermatology clinics and data from two different sources; a patient survey and a
retrospective chart review. Information about HRQoL (EQ-5D AND EQ-VAS), Der-
matology Life Quality Index (DLQI), disease severity, resource utilisation in health
care and productivity losses was collected from patient questionnaires. Patient
characteristics and type of treatment were collected from patient records.
RESULTS:During the study period, 16% of the patients used only emollients and/or
topical corticosteroids and 31% used systemic treatment (not biological drugs).
During part of or during the whole 12 months period 53% received biological treat-
ment. Mean direct cost per patient related to in- and out-patient care was esti-
mated to DKK10,682, and indirect cost was DKK9,668. Cost for drugs was DKK88,534
and cost for light treatment was DKK3,775 per patient. Indirect costs were
DKK4,300 for patients with no or minor psoriasis problems and DKK22,000 for
patients with moderate to very severe problems. Light treatment and hospitalisa-
tion costs made up the greatest part in patients receiving local topical treatment.
These costs were also higher in the topical group than in all other treatment
groups. The mean QoL values for all patients were: EQ-5D 0.76, EQ-VAS 74, and DLQI
5.0. The latter value corresponds to “small effect on patient’s life”. Fewer patients
treated with biological drugs experienced problems with treatment than other
treatment groups. CONCLUSIONS: Patients with more extensive psoriasis prob-
lems experienced lower QoL and a larger disease burden. Indirect costs increased
with disease severity. Costs increased with the use of more potent drugs (biological
and systemic drugs).
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SARCOID POSTERIOR UVEITIS VERSUS STANDARD OF CARE: COMPARING
INFLIXIMAB TO METHOTREXATE AND SYSTEMIC STEROIDS
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A505V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
